PDRN (Polydeoxyribonucleotide, Salmon DNA)

What the material is

Proposed mechanisms

Two routes appear consistently in the literature. The first is receptor-mediated: PDRN preparations have been reported to act as agonists at the adenosine A2A receptor, with A2A antagonists blunting the observed effects in several experimental systems. The second is metabolic: as fragments are degraded, the released nucleotides and nucleosides can enter the salvage pathway, providing precursors for cells that would otherwise rely on de novo purine synthesis.

Reported research areas

• Angiogenesis assays, where VEGF expression and endothelial tube formation are common endpoints.
• Fibroblast cultures examining proliferation, migration and collagen or matrix-protein output.
• Rodent wound and burn models measuring closure rate and histological organisation.
• Inflammatory studies looking at cytokine expression consistent with A2A-mediated signalling.
• Dermatological and aesthetic formulation science, where PDRN and longer-chain PN preparations are compared.

Evidence limits

Store vials refrigerated at 2–8 °C, upright and shielded from light, and do not freeze — freeze–thaw cycling can alter the fragment-size distribution that defines the material. Let a vial equilibrate to room temperature before opening so condensation does not enter it, and swab the closure with 70% isopropyl alcohol before any draw. The solution is supplied at a fixed 2%, so dilute into buffer or vehicle rather than concentrating; use aseptic technique and a fresh sterile tip or needle for each withdrawal. Inspect for cloudiness, colour change or particulates before use, and record the lot number so results can be tied to a specific size profile.